On the other hand, in HER2-positive breast cancer, phase II (GEICAM/2010-04) trials of DA in combination with trastuzumab and paclitaxel as a first-line treatment showed good efficacy [35]. This evidence concerns the gene ERBB2 and breast carcinoma.